TIL Instil Bio, Inc.
USHealthcareAs of 2026-07-09 16:00
Why TIL matters now
Instil Bio, Inc. (TIL) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.66 with -1.54% on the session and $51.9M in market capitalization; recent performance reads 1-month -6.48% and YTD -31.82%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-4.2M, and EPS of $-0.62. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -66.4%.
The latest indexable market news headline is "Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $7.00; recent insider activity includes Binder Gwendolyn filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.46
P/S
0.00
EV/EBITDA
-3.15
DCF Value
$-11.77
FCF Yield
-66.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-39.8%
ROA
-23.6%
ROIC
-27.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-4.2M | $-0.62 |
| Q4 2025 | $0.00 | $-8.2M | $-1.21 |
| FY 2025 | $0.00 | $-71.4M | $-10.70 |
| Q3 2025 | $0.00 | $-13.6M | $-2.01 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.91
Instil Bio, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on devising novel therapeutic options for individuals battling cancer. A cornerstone of their research involves the advancement of autologous tumor-infiltrating lymphocyte (TIL) cell therapies. Their developmental portfolio features ITIL-168, currently under investigation for a range of malignancies including melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer. Another promising candidate, ITIL-306, is engineered to identify folate receptor alpha (FOLR1) and is being explored for gynecological cancers, non-small cell lung cancer, renal cancer, and other conditions. This company was founded in 2018 and has its principal office situated in Dallas, Texas.